Cystic Fibrosis Clinical Trial Pipeline Expands as 50+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Vertex Pharmaceuticals, Armata Pharmaceuticals, Krystal Biotech, 4D Molecular Therapeutics, SpliSense, Verona Pharma

DelveInsight's "Cystic Fibrosis - Pipeline Insight, 2026" report provides comprehensive insights about 50+ companies developing 55+ pipeline drugs in the Cystic Fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Cystic Fibrosis treatment landscape. Learn more about the evolving Cystic Fibrosis pipeline today @ https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Cystic Fibrosis Pipeline Report

• DelveInsight's Cystic Fibrosis Pipeline Insight report depicts a robust and rapidly evolving space with 50+ active players working to develop 55+ pipeline therapies for Cystic Fibrosis treatment.
• Vertex Pharmaceuticals continues its leadership in the Cystic Fibrosis therapeutic space, advancing VX-522, an investigational mRNA therapy that aims to address the underlying cause of CF in patients who cannot benefit from CFTR modulator treatments, currently in Phase I/II development.
• Krystal Biotech is progressing KB407, an investigational, redosable gene therapy designed to deliver two copies of the CFTR gene directly to airway epithelial cells, currently in Phase I clinical development.
• Armata Pharmaceuticals is advancing AP-PA02, a therapeutic phage cocktail targeting P. aeruginosa for serious respiratory infections in patients with Cystic Fibrosis and non-cystic fibrosis bronchiectasis (NCFB), currently in Phase II clinical development.
• SpliSense is developing SPL23, an antisense oligonucleotide (ASO) targeting the W1282X mutation in Cystic Fibrosis, currently in preclinical stage development.
• The leading Cystic Fibrosis companies include Vertex Pharmaceuticals, Armata Pharmaceuticals, Krystal Biotech, 4D Molecular Therapeutics, Spirovant Sciences, Verona Pharma, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd, and others.
• Promising Cystic Fibrosis therapies in the pipeline include AP-PA02, VX-522, KB407, SPL23, and other novel candidates across discovery, preclinical, Phase I, Phase II, and Phase III stages of clinical development.

Download for updates and the latest revolution in Cystic Fibrosis care @ https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Cystic Fibrosis Emerging Drugs Profile

• AP-PA02: Armata Pharmaceuticals

AP-PA02 is a therapeutic phage cocktail that targets the pathogen P. aeruginosa, designed to treat serious respiratory infections, with an emphasis on patients with Cystic Fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFB). Phages that comprise AP-PA02 were selected with desired attributes for a product candidate targeting P. aeruginosa lung infections. AP-PA02 is comprised of a cocktail of natural P. aeruginosa phages originating from distinct families and subfamilies, targeting multiple receptor classes, functioning with compatibility and cooperativity, and further characterized by being highly potent and having a broad host range. Currently, AP-PA02 is in the Phase II stage of clinical development for the treatment of Cystic Fibrosis.

• VX-522: Vertex Pharmaceuticals

VX-522 is an investigational messenger ribonucleic acid (mRNA) therapy aimed at addressing the underlying cause of Cystic Fibrosis (CF). It is being evaluated by Vertex Pharmaceuticals to treat lung disease in people living with CF who cannot benefit from CFTR modulator treatments because they do not produce any CFTR protein that responds to CFTR modulator therapy. VX-522 is delivered to the lung through inhalation of a CFTR mRNA encapsulated by a lipid nanoparticle. Once delivered to the target lung cells, the mRNA is designed to produce functional copies of the CFTR protein. VX-522 is the result of an exclusive research collaboration established with Moderna in 2016. Currently, VX-522 is in the Phase I/II stage of clinical development for the treatment of Cystic Fibrosis.

For more information on the Cystic Fibrosis Emerging Drugs Profile, download DelveInsight's comprehensive Cystic Fibrosis Pipeline Insight report @ https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Cystic Fibrosis Pipeline Report Provides

• Detailed insights about companies developing therapies for Cystic Fibrosis, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis treatment.
• Cystic Fibrosis companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cystic Fibrosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Cystic Fibrosis market.

Learn more about Cystic Fibrosis drug opportunities in our comprehensive Cystic Fibrosis pipeline report @ https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Cystic Fibrosis Companies

There are 50+ key companies, such as Vertex Pharmaceuticals, Armata Pharmaceuticals, Krystal Biotech, 4D Molecular Therapeutics, Spirovant Sciences, Verona Pharma, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd, and others, developing therapies for Cystic Fibrosis, with Armata Pharmaceuticals having its Cystic Fibrosis drug candidate in the most advanced Phase II stage of clinical development.

DelveInsight's Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Cystic Fibrosis products have been categorized under various Molecule types such as:

• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Cystic Fibrosis treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Cystic Fibrosis Pipeline Report

• Coverage: Global
• Cystic Fibrosis Companies: Vertex Pharmaceuticals, Armata Pharmaceuticals, Krystal Biotech, 4D Molecular Therapeutics, Spirovant Sciences, Verona Pharma, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd, and others
• Cystic Fibrosis Therapies: AP-PA02, VX-522, KB407, SPL23, and others
• Cystic Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cystic Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.